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Conjugative Drug Metabolism in Liver Transplant Patients 
R. Venkataramanan, K. Kalp, M. Rabinoviteh, R. Cuellar, R.J. Ptaeheinski, L. Teperman, 
L. Makowka, G.J. Burekart, D.H. Van Thiel, and T.E. Starzl 
L IVER TRANSPLANTATION is a therapeutic option for a number of liver diseases. I While the kinetics of 
several drugs are known to be altered in liver disease, very 
little is known about drug kinetics in liver transplant 
patients. Since liver transplant patients receive multiple 
drugs, a thorough understanding of the kinetics of these 
agents is essential for optimization of drug therapy in this 
patient population. 
Previous studies from our laboratory have shown the 
oxidative drug-metabolizing capacity of the transplanted 
liver in clinically stable liver transplant patients to be similar 
to that of the normalliver,2 The objective of the present study 
was to characterize the conjugative drug metabolism of the 
liver in clincally stable liver transplant patients using acet-
aminophen (APA) as a model drug. 
METHODS 
Informed consent was obtained from seven normal and 10 liver 
transplant patients. After an overnight fasting, the subjects received 
975 mg of APA orally along with 200 mt of water. Multiple blood 
samples were collected over 12 hours and urine was also collected for 
24 hours. Plasma was analyzed for APA, and the urine was analyzed 
for APA. acetaminophen glucuronide (APA-Gl. and actaminophen 
sulfate (APA·S) by the high· pressure liquid chromatographic meth-
od. J Pharmacokinetic parameters such as disposition rate constant 
().,). disposition half·life (T'll) and the area under the plasma 
concentration versus time curve (AuC) were calculated according to 
standard methods' Student's t test was used to determine the 
presence of signIficant differences In the variOUS parameters between 
the normal subjects and the transplant patients. 
RESULTS 
All but one patient had serum bilirubin concentrations of less 
than 2.4 mg/dl. The serum creatinine concentrations were 
less than 1.9 in all but one patient. Table I lists the various 
kinetic parameters calculated from the plasma APA concen· 
tration in the two groups studied. There was no significant 
difference in any of the kinetic parameters calculated 
Table 1. Acetaminophen Klnetlclln Normal SubJectl and 
Tranlplant Patlentl 
'. T "1 Clearanca 
Sub/eetl (hr- " (hr' (mllm,") 
Normal sublects 7 0.258 ! 0.057 2.8 ! 06 287 ! 91 
liver transplant 
patients 10 0.245 ! 0.079 3. I ! 1.2 263 ! 115 
None 01 the paramelera IS significantly dillerent between the 
group •. Significsnce level: p < 0.05. 
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Table 2. Acetaminophen and ConJugal .. In Urine 
Normal Transplant 
% of Do •• Subjecta Palienta 
Excreted .. (n - 8, (n - 8, 
APA 5.3 ! 3.7 8.0 ± 8.4 
APA·G 46 ± 10 38 ~ 12 
APA·S 48 ± 13 58 :!: 19 
No significant difterence in any of the parameters. 
Significance level: p < 0.05. 
between the two groups. The harmonic mean half-lifc of 
APA was 2.7 hours (range, 2.1 to 3.6) in normal subjects and 
2.8 hours (range, 1.8 to 5.6) in transplant patients. Urinary 
excretion studies indicate similar amounts of APA, APA-G, 
and APA-S in the 24-hour urine sample (Table 2). 
DISCUSSION 
APA is often used as a model drug to study drug conjugation 
in humans. Approximately 85 to 95% of the dose adminis-
tered is converted to the glucuronide and sulfate conjugate 
and excrcted in the urine. Our studics indicate that the 
transplanted liver conjugates APA to a similar extent when 
compared to normal subjects. The fraction metabolized to 
various pathways is similar in transplant patients and normal 
subjects. This study in conjunction with our previous findings 
indiciates that the transplanted liver is capable of oxidizing 
and conjugating drugs in a normal manner. Dosing regimen 
changes are not necessary in liver transplant patients for 
drugs eliminated by conjugation pathways. 
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